0RDB.L AI Price Prediction

Track 0RDB.L's AI-powered predictions, market trends, and investment insights.

0RDB.L Sentiment 0RDB.L StockTwits 0RDB.L Reddit

Mock Tradesimulated, no real money

You don't hold 0RDB.L in your mock portfolio yet.

0RDB.L AI Price Prediction

Track 0RDB.L's AI-powered predictions, market trends, and investment insights.

0RDB.L Sentiment 0RDB.L StockTwits 0RDB.L Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)+2.7%

Price (7d)4.8%

Volume vs avg0.2x

Volatility vs normal1.3x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

Low liquidity

Avg volume 2K — may be hard to exit

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~€2.90 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

0RDB.L AI Stock Analysis

Financial Performance

bearish

The company is currently loss-making, as reflected in its negative EPS and negative PE ratio. This implies that, on a pure earnings basis, Oryzon Genomics S.A. is not yet generating sustainable profitability, which is typical for early-stage or clinical-stage biotech but still a financial risk factor. Without evidence of improving earnings trends, the financial profile leans negative from a traditional valuation perspective.

Negative EPS of -0.09 indicates the company is not profitable and is likely funding operations via cash reserves, partnerships, or capital markets.
A PE ratio of -31.19 confirms that the market is valuing the company on expectations of future success rather than current earnings, which increases sensitivity to clinical and regulatory news.
Lack of positive earnings and profitability ratios makes valuation more speculative and raises execution and financing risk compared with profitable peers.

Stock Price & Technicals

bullish

The stock trades at €2.75, modestly up 0.5% over the last month, suggesting a stable to slightly positive short-term trend. Technically, the price is well above the 200-day moving average of €2.06, which is generally a constructive signal indicating a longer-term uptrend or recovery. Despite weak fundamentals, the technical setup currently leans positive, implying market participants are willing to look through near-term losses.

Current price of €2.75 vs. 200-day moving average of €2.06 indicates the stock is trading comfortably above a key long-term support level, a classically bullish technical signal.
The 0.5% gain over the last month suggests consolidation with a slight upward bias rather than strong momentum in either direction.
With price above the 200-day moving average, many technical investors would view the trend as positive; absent an explicit RSI reading, there is no clear sign of overbought or oversold extremes from the provided data.

Alternative Data Signals

neutral

Website traffic of about 8,910 visitors per month and 11,296 LinkedIn followers indicate a modest but established digital and professional presence. However, zero current job openings suggest limited near-term expansion or hiring momentum, which tempers growth expectations. Overall, alternative data are stable but not strongly indicative of accelerating business activity.

Estimated 8,910 monthly web visitors show some ongoing interest and awareness but do not point to a surge in engagement or commercialization activity based on the data provided.
Zero job openings and 0.0% month-over-month change imply no visible hiring push, which can signal operational stability but also limited scaling or new initiatives in the near term.
A LinkedIn following of 11,296 suggests a reasonable professional footprint for a specialized biotech, but there is no evidence here of rapid follower growth that would hint at sharply rising interest.

Conclusion

neutral

The stock exhibits a constructive technical profile, trading well above its 200-day moving average, but this is offset by ongoing losses and a lack of clear profitability, leaving the overall picture balanced. Alternative data show a stable but not rapidly expanding footprint, with no strong signals of imminent operational scaling. Taken together, the outlook appears neutral, with upside dependent on future execution and catalysts rather than current financial strength.

Bullish technicals are counterbalanced by bearish fundamentals, resulting in a neutral overall stance.
Alternative data suggest stability rather than strong growth momentum, reinforcing a wait-and-see posture until clearer earnings improvement or business expansion emerges.

AI Score

Hold

Alternative4

Fundamental7

Technical3

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold 0RDB.L in your mock portfolio yet.